Presented by the European Federation of Pharmaceutical Industries and Association

Welcome to Health Conversation. Today we're asking Koen Berden, Executive Director for International Affairs at EFPIA, 'Why is a therapeutics waiver extension different to the vaccine waiver?'. Listen to hear their discussion on the challenge and how we're preparing for the future.

Why is a therapeutics waiver extension different to the vaccine waiver? 

Welcome to Health Conversation. Today we're asking Jo Atkinson, Anti-Infectives Product Lead at Pfizer, 'How can we navigate COVID-19 in a new winter health landscape?'. Listen to hear their discussion on the challenge and how we're preparing for the future.

How can we navigate COVID-19 in a new winter health landscape?

Welcome to Health Conversation. Today we're asking Claire Skentelbery, Director General of EuropaBio, 'What is the waiver impact on innovation and pandemic preparedness?'. Listen to hear their discussion on the challenge and how we're preparing for the future.

What is the waiver impact on innovation and pandemic preparedness?

Welcome to Health Conversation. Today we're asking Jesús Rueda Rodríguez, Strategies, Special Projects &amp; International Affairs Director General at MedTech Europe, 'What would a TRIPS waiver extension mean for diagnostics?'. Listen to hear their discussion on the challenge and how we're preparing for the future.

What would a TRIPS waiver extension mean for diagnostics?

Welcome to Health Conversation. Today we're asking Peter Guenter, CEO of Healthcare at Merck, 'What would be the impact of a TRIPS waiver extension?'. Listen to hear their discussion on the challenge and how we're preparing for the future.

What would be the impact of a TRIPS waiver extension?

Welcome to Health Conversation. Today we're asking Nathalie Moll, Director General at EFPIA, 'How can we support medical innovation in Europe?'. Listen to hear their discussion on the challenge and how we're preparing for the future.

How can we support medical innovation in Europe?

Welcome to 19 Conversations. Today we're asking Sara Cerdas, MEP and Mariano Votta, Director, Active Citizenship Network "How can the EU be better prepared for cross-border health threats?". Listen to hear their discussion on the challenge and how we're preparing for the future.

How can the EU be better prepared for cross-border health threats?

Welcome to 19 Conversations. Today we're asking Michel Stoffel, Senior Adviser Global Regulatory Affairs, GSK and Isabelle Bekeredjian-Ding, Head of Microbiology Division, Paul-Ehrlich-Institut "What is needed from the EMA to be better prepared for future health threats?". Listen to hear their discussion on the challenge and how we're preparing for the future.

What is needed from the EMA to be better prepared for future health threats?

Welcome to 19 Conversations. Today we're asking Prof. Paolo Bonanni, MD, Professor of Hygiene &amp; Public Health, University of Florence, Prof. Dr Joe Schmitt, Editor in Chief, Global Health Press and Sibilia Quilici, Executive Director, Vaccines Europe "What is needed from the ECDC to be better prepared for future health threats?". Listen to hear their discussion on the challenge and how we're preparing for the future.

What is needed from the ECDC to be better prepared for future health threats?

Have questions about the healthcare industry? Welcome to Health Conversation, where we will discuss today’s challenges and how we’re preparing for the future.&nbsp;Presented by the European Federation of Pharmaceutical Industries and Association.

Health Conversation

Share

Why is a therapeutics waiver extension different to the vaccine waiver?

More Episodes

View all

What is the waiver impact on innovation and pandemic preparedness?

What would a TRIPS waiver extension mean for diagnostics?

What would be the impact of a TRIPS waiver extension?